Renal Denervation: 60 Second Insights
Published: 22 March 2019
29sPart 7 Justin Davies
23sPart 8 Justin Davies
48sPart 1 | Session 1 Justin Davies Justin E Davies
40sPart 1 | Session 2 Aloke Finn Aloke V Finn
48sPart 1 | Session 3 David Kandzari
46sPart 1 | Session 4 Horst Sievert Horst Sievert
35sPart 1 | Session 5 Ajay Kirtane Ajay J Kirtane
41sPart 1 | Session 6 Robert Schwartz Robert S Schwartz
40sPart 2 | Session 1 Justin Davies Justin E Davies
38sPart 2 | Session 2 David Kandzari
A short series of 60-second insight videos on renal denervation. Hear the expert views in under one minute!
More from this programme
Thinking about patient preference, what role does RDN have in blood pressure control?
What role do you see for renal denervation in control of blood pressure in your patients?
Where does renal denervation fit in your current clinical practice?
What are the biggest barriers to blood pressure control in your patients?
Which patient groups are most receptive to RDN?
What is needed to get widespread adoption into clinical practice?
How have SPYRAL HTN-OFF and SPYRAL HTN-ON studies influenced your clinical practice?
Thinking about the SPYRAL HTN-OFF and SPYRAL HTN-ON studies, what are the take-home messages for you?
Thinking about the SPYRAL HTN-OFF and SPYRAL HTN-ON studies, for you, what are the key results?
Can you give an overview of the RDN SPYRAL clinical trial program?
Thinking about compliance, what are the advantages of RDN over pharmacological therapy?
How does renal denervation work?
Dr Horst Sievert, MD, is the Director of the CardioVascular Center Frankfurt, Sankt Katharinen, and the Department of Internal Medicine, Cardiology, and Vascular Medicine of the Sankt Katharinen Hospital in Frankfurt, Germany.
Dr Sievert is also an Associate Professor of Internal Medicine/Cardiology at the University of Frankfurt. Dr Sievert became Director of the Department of Interventional Cardiology and Angiology of the Heart Center Rotenburg in 1990, Senior Consultant at the Bethanien Hospital in Frankfurt in 1993, and Director of the CardioVascular Center Frankfurt, Sankt Katharinen in 2003. He has been the principal investigator in a number of clinical trials and has authored more than 130 manuscripts and 500 abstracts in peer-reviewed journals and 50 books and book contributions.